An Observational Study of the Safety and Effectiveness of Galantamine in the Treatment of Patients With Alzheimer's Disease Over an 18-month Period

• Status: Completed
• Trial end date: 2008-03-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this observational study is to investigate the changes in cognitive functioning, behavior, and functional improvement in Alzheimer's disease patients treated with Galantamine who are living at home (i.e. not in permanent residential care), and to obtain information regarding usual clinical practice that can be used for communicating treatment expectations to patients and supporters.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Janssen-Cilag Pty Ltd
• Treatments: Galantamine

Criteria

Inclusion Criteria:

• Patients prescribed with galantamine according to the approved New Zealand Data Sheet

• The clinical decision to prescribe Galantamine must have been made before and independently of the decision to enroll the patient in this observational study

• The patient should not have commenced Galantamine treatment before the baseline visit

• Patients must be currently living at home (i.e. not in permanent residential care)

• Availability of a supporter who has regular contact with the patient

Exclusion Criteria:

• Patients having known hypersensitivity to Galantamine

• Having severe liver impairment or severe kidney impairment

• Suffering from an uncontrolled medical condition other than dementia

• Being treated, or previously treated, with another cholinesterase inhibitor or other cholinomimetics (medications for treating Alzheimer's disease)